A probability/risk matrix of febrile neutropenia to select patients for G-CSF primary prophylaxis

被引：0
|
作者：
Ramchandani Vaswani, A. [1 ]
Faez, L. [2 ]
Selvi Miralles, M. [3 ]
Antonio-Rebollo, M. [4 ]
Font Puig, C. [3 ]
Espinosa Arranz, J. [5 ]
Biosca, M. [6 ]
Vicente Rubio, E. [7 ,8 ]
Jimenez Fonseca, P. [2 ]
Carmona-Bayonas, A.
机构：
[1] Hosp Univ Insular Gran Canaria, Las Palmas Gran Canaria, Spain
[2] Hosp Cent Asturias, Oviedo, Spain
[3] Hosp Clin Barcelona, Barcelona, Spain
[4] ICO Duran & Reynals, Barcelona, Spain
[5] Hosp Gen Ciudad Real, Ciudad Real, Spain
[6] Hosp Valle De Hebron, Barcelona, Spain
[7] Hosp Univ Insular Gran Canaria, Barcelona, Spain
[8] Hosp Univ Morales Meseguer, Murcia, Spain
来源：
EUROPEAN JOURNAL OF CANCER | 2013年 / 49卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1326
引用
收藏
页码：S275 / S276
页数：2
相关论文
共 50 条
  • [1] Integration of G-CSF in the prophylaxis and treatment of febrile neutropenia
    Siegmund, R
    Illiger, HJ
    [J]. MEDIZINISCHE KLINIK, 1996, 91 (02) : 82 - 88
  • [2] Pegfilgrastim in primary prophylaxis of febrile neutropenia in elderly patients with hematological malignanciesbendamustine and G-CSF support
    Cerchione, Claudio
    De Renzo, Amalia
    Nappi, Davide
    Di Perna, Maria
    Della Pepa, Roberta
    Pugliese, Novella
    Catalano, Lucio
    Pane, Fabrizio
    Picardi, Marco
    [J]. SUPPORTIVE CARE IN CANCER, 2019, 27 (05) : 1587 - 1588
  • [3] G-CSF for Prophylaxis of Neutropenia and febrile Neutropenia, Anemia in Cancer (2022)
    Link, Hartmut
    [J]. UROLOGIE, 2023, 62 (2): : 186 - 186
  • [4] G-CSF primary prophylaxis use and outcomes in patients receiving chemotherapy at intermediate risk for febrile neutropenia: a scoping review
    Campbell, Kim
    Chadha, Nidhi
    Dimri, Seema
    Wang, Weijia
    Li, Edward
    [J]. EXPERT REVIEW OF HEMATOLOGY, 2022, 15 (07) : 619 - 633
  • [5] G-CSF prophylaxis of febrile neutropenia and infections after chemotherapy
    Link, H.
    [J]. ONKOLOGE, 2014, 20 (03): : 268 - 270
  • [6] Pegfilgrastim in primary prophylaxis of febrile neutropenia in elderly patients with hematological malignancies—bendamustine and G-CSF support
    Claudio Cerchione
    Amalia De Renzo
    Davide Nappi
    Maria Di Perna
    Roberta Della Pepa
    Novella Pugliese
    Lucio Catalano
    Fabrizio Pane
    Marco Picardi
    [J]. Supportive Care in Cancer, 2019, 27 : 1587 - 1588
  • [7] Real-world cost-effectiveness of primary prophylaxis with G-CSF biosimilars in patients at intermediate/high risk of febrile neutropenia
    Cornes, Paul
    Kelton, John
    Liu, Rongzhe
    Zaidi, Omer
    Stephens, Jennifer
    Yang, Jingyan
    [J]. FUTURE ONCOLOGY, 2022, 18 (16) : 1979 - 1996
  • [8] Chemotherapy-induced febrile neutropenia: primary G-CSF prophylaxis indicated during docetaxel cycles
    van Dooijeweert, C.
    van der Wall, E.
    Baas, I. O.
    [J]. NETHERLANDS JOURNAL OF MEDICINE, 2019, 77 (09): : 310 - 316
  • [9] Febrile neutropenia primary prophylaxis with granulocyte-colony stimulating factors (G-CSF) in breast cancer
    Younis, T.
    Rayson, D.
    Skedgel, C.
    [J]. CANCER RESEARCH, 2013, 73
  • [10] History of chronic comorbidity and risk of chemotherapy-induced febrile neutropenia in cancer patients not receiving G-CSF prophylaxis
    Chao, C.
    Page, J. H.
    Yang, S. -J.
    Rodriguez, R.
    Huynh, J.
    Chia, V. M.
    [J]. ANNALS OF ONCOLOGY, 2014, 25 (09) : 1821 - 1829
12345